NurExone's Exosome Therapy Shows Promise in Spinal Cord Injury Repair

TORONTO and HAIFA, Israel – August 14, 2026 – In the high-stakes world of biotechnology, where hope is often measured in microscopic changes, NurExone Biologic Inc. has delivered a significant update. The company announced new preclinical data providing a compelling biological explanation for the functional recovery previously seen in animal models of acute spinal cord injury (SCI) treated with its lead candidate, ExoPTEN. The findings, which demonstrate a neuroprotective effect on the vital coating of nerve fibers, strengthen the scientific foundation of the company's exosome-based therapy and illuminate its path toward human clinical trials.

For the hundreds of thousands of people who suffer spinal cord injuries each year, current treatments offer stabilization and rehabilitation but little hope for true regeneration. NurExone's latest results suggest a new mechanism for intervention, one that doesn't just halt damage but may actively preserve the structures necessary for recovery.

Unlocking the Biology of Recovery

The new tissue analysis centers on a crucial component of the nervous system: myelin. Much like insulation around an electrical wire, the myelin sheath protects nerve fibers (axons) and enables the rapid transmission of signals. Damage to this sheath, a common consequence of SCI, severely impairs neurological function. NurExone's study found that two months after injury, animals treated with ExoPTEN had significantly higher numbers of cells positive for Myelin Basic Protein (MBP)—a key building block of myelin—in the areas surrounding the injury site compared to untreated controls.

This isn't just a statistical victory; it's a biological clue that helps solve a puzzle. The company had previously reported that animals treated with ExoPTEN regained significant motor function. Now, they have a potential explanation for how that happened. By preserving the myelin sheath, ExoPTEN may be protecting the surviving neural tissue and the very infrastructure needed for nerve signaling and repair.

“These results are important as we continue to gain biological rationale behind the functional recovery observed previously in ExoPTEN-treated animals,” said Dr. Tali Kizhner, Director of Research and Development at NurExone. “These findings provide additional preclinical evidence supporting ExoPTEN’s potential neuroprotective effect and may help us better understand how ExoPTEN could support neural tissue preservation and recovery following injury.”

ExoPTEN’s approach is a sophisticated example of targeted regenerative medicine. It uses exosomes—tiny, naturally occurring vesicles that act as cellular messengers—derived from bone marrow. These exosomes are loaded with a proprietary therapeutic cargo: small interfering RNA (siRNA) designed to silence the PTEN gene. PTEN is a well-known inhibitor of a cellular growth pathway called mTOR, which plays a critical role in nerve regeneration. By delivering a payload that temporarily shuts down this inhibitor, ExoPTEN aims to unlock the body's own potential for axonal growth and repair.

A New Contender in a High-Stakes Race

The medical need for an effective SCI therapy is immense. The current standard of care is largely supportive, leaving a vast therapeutic void that numerous companies are racing to fill. The competitive landscape includes stem cell therapies, gene therapies, and advanced biomaterials, each with its own set of promises and challenges. Stem cell treatments, for example, face hurdles related to immune rejection, uncontrolled differentiation, and tumorigenicity.

NurExone's exosome-based strategy offers several potential advantages. As a “cell-free” therapy, ExoPTEN sidesteps many of the safety concerns associated with transplanting living cells. Furthermore, its delivery method is a significant differentiator. The therapy is administered intranasally, a minimally invasive route that leverages the nose-to-brain pathway to deliver the therapeutic exosomes directly to the central nervous system, bypassing the formidable blood-brain barrier. Preclinical data has also shown that ExoPTEN is effective even when administered up to seven days post-injury, an extended therapeutic window that could be a game-changer in real-world clinical settings where immediate treatment isn't always possible.

By targeting a specific and well-validated regenerative pathway (PTEN/mTOR) with a sophisticated delivery vehicle, NurExone is positioning ExoPTEN not as a general supportive treatment, but as a precision tool designed to actively promote repair.

Charting a Course from Data to Drug

With this robust new data in hand, NurExone is fortifying its case for regulators and investors alike. The next major milestone is the submission of an Investigational New Drug (IND) application to agencies like the U.S. Food and Drug Administration (FDA), a critical step to commencing human trials. While the regulatory pathway for exosome therapies is still maturing, the detailed mechanistic data NurExone is accumulating will be invaluable in these discussions.

Building a successful biotech company requires more than just good science; it demands a sound financial and corporate strategy. Recognizing this, NurExone, which is publicly listed in Canada, the U.S., and Germany, recently entered into an investor awareness agreement with the Austrian firm BullVestor Medien GmbH. This move is designed to enhance the company’s visibility in key European capital markets. For a preclinical company facing the long and expensive road of clinical development, building a broad and stable investor base is not just a promotional activity—it's a core part of its survival and growth strategy.

By systematically de-risking its lead asset with strong scientific evidence, NurExone strengthens its position to attract the necessary capital and potential pharmaceutical partners to carry ExoPTEN through multi-phase clinical trials and, ultimately, to patients.

The Dawn of the Exosome Era

NurExone's progress with ExoPTEN is a compelling case study in a broader technological shift: the rise of exosomes as a therapeutic platform. These nanoscale particles, once dismissed as cellular debris, are now understood to be fundamental players in intercellular communication. Harnessing them for medicine opens up a new paradigm for treating a wide range of diseases.

Their promise lies in their ability to deliver diverse therapeutic cargoes—from small molecules to genetic material—with a natural talent for targeting specific tissues. However, the field is not without challenges. Establishing standardized, scalable manufacturing processes and ensuring consistent quality and potency are critical hurdles the entire industry must overcome for clinical and commercial success.

NurExone's work provides a glimpse of this future. The company's platform has already shown promise beyond SCI, with preclinical data demonstrating recovery in models of optic nerve damage. This suggests the underlying technology could be adapted for a variety of currently intractable central nervous system injuries. As research continues to refine the production and application of these powerful biological messengers, therapies like ExoPTEN may one day transform the standard of care for some of medicine’s most difficult challenges.